Sangamo BioSciences Stock News

Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

The heavy selling pressure might have exhausted for Sangamo (SGMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in

Gene editing may be a relatively new industry, but it already has a lot of promise, especially for savvy biotech investors. Several gene editing companies have notable upsides, meaning that no matter

These cutting-edge biotech companies quickly fell out of favor with investors this week.

CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease

Penny stocks to buy according to analysts. Are they right?

Sangamo Therapeutics is developing groundbreaking genomic and cell therapies for the treatment of some of the worst diseases known to man. I review the company's recent progress and will provide my vi

Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Na

Sangamo (SGMO) delivered earnings and revenue surprises of 2.86% and 2.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Shares have fallen by 30% so far in 2022. Durability and safety for the Fabry disease gene therapy program continues to look best-in-class and enrollment should accelerate due to investigator enthusia

Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Rob

BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES PARTICIPATION AT UPCOMING INVESTOR CONFERENCES

Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Rob Sch

Sangamo (SGMO) delivered earnings and revenue surprises of 6.25% and 1.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Sangamo (SGMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th